77992-46-2Relevant articles and documents
Synthesis of 2,3-Disubstituted 5-Iodo-1H-Pyrrolo[2,3-b]pyridines via Fischer Cyclization
Alekseyev, Roman S.,Amirova, Sabina S.,Terenin, Vladimir I.
, p. 2656 - 2663 (2017/09/26)
A simple and convenient procedure for the preparation of some unknown 2,3-disubstituted 5-iodo-1H-pyrrolo[2,3-b]pyridines from readily available starting materials by Fischer indole cyclization in polyphosphoric acid is described. The present methodology provides an alternative synthetic approach to the synthesis of 5-iodo-7-azaindole scaffold. All synthesized compounds were characterized by IR, MS, 1H and 13C NMR, and elemental analysis.
A novel pyrazolopyridine with in vivo activity in Plasmodium berghei- and Plasmodium falciparum-infected mouse models from structure-activity relationship studies around the core of recently identified antimalarial imidazopyridazines
Le Manach, Claire,Paquet, Tanya,Brunschwig, Christel,Njoroge, Mathew,Han, Ze,Gonzàlez Cabrera, Diego,Bashyam, Sridevi,Dhinakaran, Rajkumar,Taylor, Dale,Reader, Janette,Botha, Mariette,Churchyard, Alisje,Lauterbach, Sonja,Coetzer, Theresa L.,Birkholtz, Lyn-Marie,Meister, Stephan,Winzeler, Elizabeth A.,Waterson, David,Witty, Michael J.,Wittlin, Sergio,Jiménez-Díaz, María-Belén,Santos Martínez, María,Ferrer, Santiago,Angulo-Barturen, I?igo,Street, Leslie J.,Chibale, Kelly
supporting information, p. 8713 - 8722 (2015/11/25)
Toward improving pharmacokinetics, in vivo efficacy, and selectivity over hERG, structure-activity relationship studies around the central core of antimalarial imidazopyridazines were conducted. This study led to the identification of potent pyrazolopyridines, which showed good in vivo efficacy and pharmacokinetics profiles. The lead compounds also proved to be very potent in the parasite liver and gametocyte stages, which makes them of high interest.
Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
-
Paragraph 0148; 0149, (2015/01/18)
The present invention relates to compounds assumed to be capable of modulating the activity of the proteins ScyI1 and Grk5, thereby regulating the expression and/or release of insulin as well as to pharmaceutical compositions containing such compounds and the use thereof especially for the treatment of a metabolic disease such as diabetes, obesity and impaired adipogenesis.